Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
8607 participants
OBSERVATIONAL
2015-05-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00494871
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
NCT03284762
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
NCT01750788
Rivaroxaban Evaluation in Real Life Settings
NCT02444221
Rivaroxaban Acute Stroke Safety Study
NCT02279940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rivaroxaban
Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
Rivaroxaban (Xarelto, BAY59-7939)
As prescribed by treating physicians
Vitamin K antagonists (VKA)
NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
Vitamin K antagonists
As prescribed by treating physicians
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban (Xarelto, BAY59-7939)
As prescribed by treating physicians
Vitamin K antagonists
As prescribed by treating physicians
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of NVAF on start date of study or anytime during 365 days before this date
* Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date)
* Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.
Exclusion Criteria
* Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date
* Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period
* Prescriptions of \< 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen, LP
INDUSTRY
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DBOX 2014/00799
Identifier Type: OTHER
Identifier Source: secondary_id
18073
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.